checkAd

     247  0 Kommentare Sesen Bio Strengthens Leadership Team

    Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced industry leaders to several key roles:

    • Mark R. Sullivan to General Counsel and Corporate Secretary
    • Erin Clark to Vice President, Corporate Strategy and Investor Relations
    • Monica Forbes to Vice President, Finance
    • Omar Rifi to Vice President, Business Development and Alliance Management

    “The financing in the second quarter has enabled us to build additional capabilities as we work diligently to prepare for the anticipated initiation of our BLA submission for Vicinium in the fourth quarter,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “I’m delighted to have Mark, Erin, Monica and Omar in these key leadership positions to help accelerate the Company’s progress towards key milestones. All four of these individuals not only bring impressive track records and diverse skill sets to Sesen, but also believe very strongly in our mission to save and improve the lives of patients with cancer.”

    Mark R. Sullivan has more than 20 years of legal experience in the life sciences and healthcare industries. Mr. Sullivan joined Sesen Bio in April 2018 as the acting general counsel. Prior to joining Sesen, he provided outsourced in-house counsel services to a variety of companies including Sandoz Inc. and Bayer Healthcare. Prior to that, Mr. Sullivan served as the general counsel, chief compliance officer and secretary of MModal Inc., a public healthcare IT company for 9 years, until the company was taken private by One Equity Partners in July 2012. Mr. Sullivan began his career as an attorney at the law firms of Pepper Hamilton LLP and Drinker Biddle & Reath LLP, where his practice focused on corporate and securities matters. Mr. Sullivan holds a J.D. from Rutgers University School of Law and a Bachelor of Arts from the University of Pennsylvania.

    Erin Clark brings extensive leadership experience in strategy and commercialization of late-stage life science companies. Ms. Clark joined Sesen Bio in January 2019 as the executive director of strategy planning and investor relations. Prior to joining Sesen, Ms. Clark held various leadership roles at Trevena, Inc. and Orexigen Therapeutics, Inc., where she helped drive commercialization and realization of external value drivers for lead assets in development and approved marketed products. Prior to her roles at Trevena and Orexigen, Ms. Clark worked as a consultant at Deloitte where she led quantitative and qualitative market assessments for small and large life science clients. Ms. Clark began her career at Johnson and Johnson where she played key roles in supporting multi-billion-dollar products across the pharmaceutical portfolio. Ms. Clark received her Bachelor of Science in Finance from Pennsylvania State University.

    Seite 1 von 4


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Sesen Bio Strengthens Leadership Team Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced industry …